Highly Potent Triazole-Based Tubulin Polymerization Inhibitors

We describe the synthesis and biological evaluation of a series of tubulin polymerization inhibitors that contain the 1,2,4-triazole ring to retain the bioactive configuration afforded by the cis double bond in combretastatin A-4 (CA-4). Several of the subject compounds exhibited potent tubulin poly...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 50; no. 4; pp. 749 - 754
Main Authors Zhang, Qiang, Peng, Youyi, Wang, Xin I, Keenan, Susan M, Arora, Sonia, Welsh, William J
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 22.02.2007
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We describe the synthesis and biological evaluation of a series of tubulin polymerization inhibitors that contain the 1,2,4-triazole ring to retain the bioactive configuration afforded by the cis double bond in combretastatin A-4 (CA-4). Several of the subject compounds exhibited potent tubulin polymerization inhibitory activity as well as cytotoxicity against a variety of cancer cells including multi-drug-resistant (MDR) cancer cell lines. Attachment of the N-methyl-5-indolyl moiety to the 1,2,4-triazole core, as exemplified by compound 7, conferred optimal properties among this series. Computer docking and molecular simulations of 7 inside the colchicine binding site of tubulin enabled identification of residues most likely to interact strongly with these inhibitors and explain their potent anti-tubulin activity and cytotoxicity. It is hoped that results presented here will stimulate further examination of these substituted 1,2,4-triazoles as potential anti-cancer therapeutic agents.
Bibliography:istex:2238F8D70DBF71F9855D33E27744110F27D17F4C
ark:/67375/TPS-NTK19WB0-H
Medline
NIH RePORTER
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: School of Biological Sciences, University of Northern Colorado, Greeley, CO 80639.
Present address: Intra-Cellular Therapies, Inc., 3960 Broadway, New York, NY 10032.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm061142s